Brain Health & TB006

Welcome to the Brain Health page!

Here we have more information on TB006 and the Expanded Access Program

TB006 Brings Multifaceted Hope for Dementia and Beyond

TB006 is an investigational medicine offering a potentially anti-inflammatory approach to treating Alzheimer's disease (AD) and a wide range of dementias. This investigational drug targets Galectin-3 (Gal3), a protein with dual roles in the progression of these diseases:

By selectively blocking Gal3, TB006 potentially disrupts both of these pathways. It potentially prevents harmful brain aggregates while reducing neuroinflammation, potentially reversing some damage and restoring cognitive function. Early clinical trials show promising results for treating various dementias, including:

Beyond these specific types, TB006's unique mechanism of action suggests its potential to benefit individuals with other dementias as well. This opens up exciting possibilities for the future of dementia treatment.

TB006 offers hope for millions of individuals and their families. It represents a potentially significant breakthrough in the fight against dementia, paving the way for a brighter future and improved quality of life for those affected by this debilitating condition.

Are there any ongoing clinical trials for TB006?

TrueBinding has completed the Phase 1b/2 trial and has completed recruitment for the Open Label Extension (OLE) trial for TB006 combating Alzheimer’s disease. 

Until the next trial has been initiated, there are no actively recruiting trials for TB006. Therefore we have opted to offer the Expanded Access Program (EAP) to provide patients continued access to the breakthrough drug.

What is the Expanded Access Program (EAP)?

Expanded access, also known as compassionate use, is a program that allows patients with severe or life-threatening illnesses to receive investigational medications outside of clinical trials. It provides access to these medications, which have not yet been approved by the FDA, when there are no other approved treatment options available. Patients eligible for this program may have already tried and failed approved medications, or they may be unable to take currently available medications due to side effects or contraindications. Additionally, expanded access programs cater to situations where no clinical trials are available or the patient does not meet the eligibility criteria for such trials. By granting access to investigational medications, these programs offer a compassionate approach to provide potential benefits to patients who have exhausted all other alternatives for their conditions.

How can I, or my loved one, participate?

If you are a patient or caretaker: